Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Eiber

Showing results (221-230 of 377) with videos related to

Pageof 38
Sort By:
Clinical Nuclear Medicine|June 9, 2016
Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate CancerIsabel Rauscher, Tobias Maurer, Michael Souvatzoglou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 14, 2015
Evaluation of 18F-fluoride PET/MR and PET/CT in patients with foot pain of unclear causeIsabel Rauscher, Ambros J Beer, Christoph Schaeffeler, et al.
Nature Reviews. Urology|December 6, 2022
Using PSMA imaging for prognostication in localized and advanced prostate cancerMatthew J Roberts, Tobias Maurer, Marlon Perera, et al.
BMC Cancer|June 9, 2015
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patientsMark Thalgott, Brigitte Rack, Matthias Eiber, et al.
International Journal of Molecular Sciences|July 24, 2021
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate CancerMagdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, et al.
BMC Cancer|May 8, 2021
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocolJeremie Calais, Shaojun Zhu, Nader Hirmas, et al.
Radiology|February 25, 2025
Automated CT Measurement of Total Kidney Volume for Predicting Renal Function Decline after <sup>177</sup>Lu Prostate-specific Membrane Antigen-I&T Radioligand TherapyLisa Steinhelfer, Friederike Jungmann, Manuel Nickel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2026
Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRITürkay Hekimsoy, Andreas P Sauter, Robert Tauber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2025
[<sup>225</sup>Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and KidneysAlexander Wurzer, Baiqing Sun, Samaa Saleh, et al.
European Urology Oncology|September 22, 2020
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center StudyAndrew T Lenis, Aydin Pooli, Patrick M Lec, et al.
Pageof 38

Showing results (221-230 of 377) with videos related to

Sort By:
Pageof 38
Clinical Nuclear Medicine|June 9, 2016
Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate CancerIsabel Rauscher, Tobias Maurer, Michael Souvatzoglou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 14, 2015
Evaluation of 18F-fluoride PET/MR and PET/CT in patients with foot pain of unclear causeIsabel Rauscher, Ambros J Beer, Christoph Schaeffeler, et al.
Nature Reviews. Urology|December 6, 2022
Using PSMA imaging for prognostication in localized and advanced prostate cancerMatthew J Roberts, Tobias Maurer, Marlon Perera, et al.
BMC Cancer|June 9, 2015
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patientsMark Thalgott, Brigitte Rack, Matthias Eiber, et al.
International Journal of Molecular Sciences|July 24, 2021
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate CancerMagdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, et al.
BMC Cancer|May 8, 2021
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocolJeremie Calais, Shaojun Zhu, Nader Hirmas, et al.
Radiology|February 25, 2025
Automated CT Measurement of Total Kidney Volume for Predicting Renal Function Decline after <sup>177</sup>Lu Prostate-specific Membrane Antigen-I&T Radioligand TherapyLisa Steinhelfer, Friederike Jungmann, Manuel Nickel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2026
Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRITürkay Hekimsoy, Andreas P Sauter, Robert Tauber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2025
[<sup>225</sup>Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and KidneysAlexander Wurzer, Baiqing Sun, Samaa Saleh, et al.
European Urology Oncology|September 22, 2020
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center StudyAndrew T Lenis, Aydin Pooli, Patrick M Lec, et al.
Pageof 38